ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Revenue of ADMA Biologics, Inc. (ADMA)
Revenue in 2023 (TTM): $258.21 M
According to ADMA Biologics, Inc.'s latest financial reports the company's current revenue (TTM) is $258.21 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of ADMA Biologics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $258.21 M | $88.22 M | $29.96 M | $-28,239,000 | $-28,239,000 |
| 2022 | $154.08 M | $35.27 M | $-39,239,283 | $-65,903,950 | $-85,183,323 |
| 2021 | $80.94 M | $1.17 M | $-57,875,431 | $-71,647,618 | $-84,452,877 |
| 2020 | $42.22 M | $-19,071,643 | $-64,039,926 | $-75,748,548 | $-87,605,086 |
| 2019 | $29.35 M | $-10,155,155 | $-40,005,926 | $-48,279,317 | $-57,045,374 |
| 2018 | $16.99 M | $-25,209,345 | $-56,774,264 | $-65,743,445 | $-65,743,445 |
| 2017 | $22.76 M | $-6,403,761 | $-37,182,849 | $-43,758,975 | $-43,758,975 |
| 2016 | $10.66 M | $4.3 M | $-16,806,006 | $-19,515,151 | $-19,515,151 |
| 2015 | $7.18 M | $2.87 M | $-15,006,156 | $-17,969,930 | $-17,969,930 |
| 2014 | $5.92 M | $2.17 M | $-16,078,672 | $-17,364,887 | $-16,813,163 |
| 2013 | $3.07 M | $1.04 M | $-14,741,678 | $-15,527,246 | $-15,527,246 |
| 2012 | $1.12 M | $449.06 K | $-7,706,156 | $-7,918,928 | $-7,301,313 |
| 2011 | $ | $ | $-26,464 | $-26,460 | $-26,460 |
| 2010 | $ | $ | $-20,530 | $-20,526 | $-20,526 |
| 2009 | $ | $ | $-20,009,000 | $-20,009,000 | $-20,009,000 |
| 2008 | $ | $ | $-24,891,000 | $-24,891,000 | $-24,891,000 |
| 2007 | $ | $ | $-29,687,000 | $-29,687,000 | $-29,687,000 |